Continuing opnurasib treatment for patients who are benefiting
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial allows people who are already taking opnurasib in another Novartis study and seeing good results to keep receiving it. The goal is to let them continue treatment without interruption.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently in a Novartis study taking opnurasib, either alone or with other drugs.
- You have received at least 6 cycles of opnurasib in that study.
- Your doctor believes you are still getting benefit from the treatment, like slowed disease or improved symptoms.
- You have not permanently stopped opnurasib for any reason other than to join this rollover study.
- You are willing to follow the birth control rules from your original study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a “rollover” study for people who were already taking a Roche (or Genentech) cancer study medicine. It checks whether continuing the same study treatment (when commercial options aren’t available) can keep helping you.
This study is for people who are already taking the targeted therapy sotorasib (with or without another drug called panitumumab) in an Amgen clinical trial and are still doing well. It lets you keep receiving the same treatment after your original study ends, so you don't have to stop a medicine that is working for you.
This trial tests a new targeted therapy (olomorasib) combined with standard treatments for people with a specific type of non-small cell lung cancer that has a KRAS G12C mutation. Depending on the stage of your cancer, you may receive it before or after surgery, or along with chemotherapy and radiation.
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
This trial tests an oral targeted drug called Garsorasib for people with advanced lung cancer that has a specific KRAS G12C mutation and has not received previous treatment for advanced disease. The goal is to see if it can shrink tumors and improve outcomes.
Hear when a new Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.